Bone morphogenetic protein 2 stimulates osteoclast differentiation and survival supported by receptor activator of nuclear factor-κB ligand

Endocrinology

Volumn 142, Issue 8, 2001, Pages 3656-3662

  Itoh, Kanami ^a   Udagawa, Nobuyuki ^a   Katagiri, Takenobu ^a   Iemura, Shunichiro ^b   Ueno, Naoto ^b   Yasuda, Hisataka ^c   Higashio, Kanji ^d   Quinn, Julian M W ^e   Gillespie, Matthew T ^e   Martin, T John ^e   Suda, Tatsuo ^a   Takahashi, Naoyuki ^a  

^a SHOWA UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE FOR BASIC BIOLOGY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d SNOW BRAND MILK PRODUCTS CO LTD   (Japan)

^e ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN A; BONE MORPHOGENETIC PROTEIN 2; COLONY STIMULATING FACTOR 1; OSTEOCLAST DIFFERENTIATION FACTOR; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE RELEASE; ELECTROPHORESIS; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 17844398732     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.142.8.8300     Document Type: Article

References (58)

1. Osteoblastic cells are involved in osteoclast formation
2. Origin of osteoclasts: Mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells
3. Modulation of osteoclast differentiation
4. Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors
5. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene
6. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL
7. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function
8. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells
9. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation
10. Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures
11. A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro
12. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis
13. RANK is essential for osteoclast and lymph node development
14. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand
15. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis
16. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density
17. TR1, a new member of the tumor necrosis factor receptor superfamily, induces fibroblast proliferation and inhibits osteoclastogenesis and bone resorption
18. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro
19. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification
20. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin
21. Novel regulators of bone formation: Molecular clones and activities
22. Activation of the bone-derived latent TGF beta complex by isolated osteoclasts
23. Signal transduction via serine/threonine kinase receptors
24. A truncated bone morphogenetic protein receptor affects dorsal-ventral patterning in the early Xenopus embryo
25. A mammalian serine/threonine kinase receptor specifically binds BMP-2 and BMP-4
26. Human type II receptor for bone morphogenic proteins (BMPs): Extension of the two-kinase receptor model to the BMPs
27. Studies with a Xenopus BMP receptor suggest that ventral mesoderm-inducing signals override dorsal signals in vivo
28. Identification of type I receptors for osteogenic protein-1 and bone morphogenetic protein-4
29. Interaction between soluble type I receptor for bone morphogenetic protein and bone morphogenetic protein-4
30. Identification of the ligand-binding site of the BMP type IA receptor for BMP-4
31. Tumor necrosis factor α stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction
32. 3 in osteoclast differentiation and function
33. Osteoclast-like cell formation and its regulation by osteotropic hormones in mouse bone marrow cultures
34. Activation of NF-κB is involved in the survival of osteoclasts promoted by interleukin-1
35. Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function
36. The non-osteogenic mouse pluripotent cell line, C3H10T1/2, is induced to differentiate into osteoblastic cells by recombinant human bone morphogenetic protein-2
37. Recombinant human bone morphogenetic protein-2 stimulates osteoblastic maturation and inhibits myogenic differentiation in vitro
38. Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage
39. Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors
40. Essential requirement of BMPs-2/4 for both osteoblast and osteoclast formation in murine bone marrow cultures from adult mice: Antagonism by noggin
41. Bone morphogenetic protein-2 enhances osteoclast formation mediated by interleukin-1α through upregulation of osteoclast differentiation factor and cyclooxygenase-2
42. TGF-β enhances osteoclast differentiation in hematopoietic cell cultures stimulated with RANKL and M-CSF
43. Endogenous production of TGF-β is essential for osteoclastogenesis induced by a combination of receptor activator of NF-κB ligand and macrophage-colony-stimulating factor
44. Activin A is an essential cofactor for osteoclast induction
45. A role for TGFβ(1) in osteoclast differentiation and survival
46. Increased expression of TGF-β2 in osteoblasts results in an osteoporosis-like phenotype
47. Inhibition of TGF-β receptor signaling in osteoblasts leads to decreased bone remodeling and increased trabecular bone mass
48. Gene expression of transforming growth factor-β 1 and its type II receptor in giant cell tumors of bone. Possible involvement in osteoclast-like cell migration
49. Stimulatory effect of bone morphogenetic protein-2 on osteoclast-like cell formation and bone-resorbing activity
50. Macrophage colony-stimulating factor and interleukin-1α maintain the survival of osteoclast-like cells
51. Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: Receptor activator of NF-κB ligand
52. Direct stimulation of osteoclastic bone resorption by bone morphogenetic protein (BMP)-2 and expression of BMP receptors in mature osteoclasts
53. Granulocyte-macrophage colony stimulating factor suppresses lipopolysaccharide-induced osteoclast-like cell formation in mouse bone marrow cultures
54. Interleukin-18 (interferon-γinducing factor) is produced by osteoblasts and acts via granulocyte/macrophage colony-stimulating factor and not via interferon-γ to inhibit osteoclast formation
55. 2 cooperates with TRANCE in osteoclast induction from hemopoietic precursors: Synergistic activation of differentiation, cell spreading, and fusion
56. Prostaglandin G/H synthase-2 is required for maximal formation of osteoclast-like cells in culture
57. Transcriptional control by the TGF-β/Smad signaling system
58. Reciprocal role of ERK and NF-κB pathways in survival and activation of osteoclasts